Jan 24, 2022–The Canadian Intellectual Property Office intends to grant RhoVac’s patent application for RV001 (onilcamotide) cancer vaccineDec 15, 2021–RhoVac's co-founder and board member sells a fraction of his shares to cover taxes on holdings (regulatory)Dec 09, 2021–Another clean interim safety review of RhoVac’s clinical phase IIb study in prostate cancer (regulatory)
